NCT03722407View on ClinicalTrials.gov

Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

August 28, 2019

Primary Completion Date

September 19, 2022

Study Completion Date

June 1, 2026

Conditions
Chronic Myelomonocytic LeukemiaLeukemia
Interventions
DRUG

Ruxolitinib

Ruxolitinib 5 mg tablets, 4 per dose

Trial Locations (5)

10021

Weill Medical College of Cornell University, New York

21231

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

44195

Cleveland Clinic, Cleveland

02215

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Incyte Corporation
All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT03722407 - Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion | Biotech Hunter | Biotech Hunter